Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma

Human Pathology

Volumn 43, Issue 12, 2012, Pages 2197-2206

  Rahman, Munmun ^a   Nakayama, Kentaro ^a   Rahman, Mohammed Tanjimur ^a   Nakayama, Naomi ^a   Ishikawa, Masako ^a   Katagiri, Atsuko ^a   Iida, Kouji ^a   Nakayama, Satoru ^b   Otsuki, Yoshiro ^b   Shih, Ie Ming ^c   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

BRAF; KRAS; Mutation; Ovarian clear cell carcinoma; PIK3CA

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; B RAF KINASE; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TEMSIROLIMUS;

ADULT; AGED; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER GRADING; CLEAR CELL CARCINOMA; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOGENESIS; PROTEIN EXPRESSION;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED, 80 AND OVER; CELL LINE, TUMOR; FEMALE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84869503560     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.03.011     Document Type: Article

References (35)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. K.R. Cho, and M. Shih Ie Ovarian cancer Annu Rev Pathol: Mech Dis 4 2009 287 313
3. R.E. Bristow, F.J. Montz, L.D. Lagasse, R.S. Leuchter, and B.Y. Karlan Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer Gynecol Oncol 72 1999 278 287
4. M. Markman, P.Y. Liu, and S. Wilczynski Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial J Clin Oncol 21 2003 2460 2465
5. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
6. T. Sugiyama, T. Kamura, and J. Kigawa Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy Cancer 88 2000 2584 2589
7. A.W. Kennedy, C.V. Biscotti, W.R. Hart, and K.D. Webster Ovarian clear cell adenocarcinoma Gynecol Oncol 32 1989 342 349
8. M. Fukunaga, K. Nomura, E. Ishikawa, and S. Ushigome Ovarian atypical endometriosis: its close association with malignant epithelial tumours Histopathology 30 1997 249 255
9. R.T. Marquez, K.A. Baggerly, and A.P. Patterson Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon Clin Cancer Res 11 2005 6116 6126
10. N. Sato, H. Tsunoda, and M. Nishida Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary Cancer Res 60 2000 7052 7056
11. E. Veras, T.L. Mao, and A. Ayhan Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases Am J Surg Pathol 33 2009 844 853
12. K.T. Kuo, T.L. Mao, and S. Jones Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma Am J Pathol 174 2009 1597 1601
13. S. Jones, T.L. Wang, and M. Shih Ie Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 330 2010 228 231
14. K.C. Wiegand, S.P. Shah, and O.M. Al-Agha ARID1A mutations in endometriosis-associated ovarian carcinomas N Engl J Med 363 2010 1532 1543
15. K.T. Kuo, T.L. Mao, and X. Chen DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma Clin Cancer Res 16 2010 1997 2008
16. I.G. Campbell, S.E. Russell, and D.Y. Choong Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 2004 7678 7681
17. J.W. Lee, Y.H. Soung, and S.Y. Kim PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas Oncogene 24 2005 1477 1480
18. K. Oda, D. Stokoe, Y. Taketani, and F. McCormick High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma Cancer Res 65 2005 10669 10673
19. Y. Samuels, Z. Wang, and A. Bardelli High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
20. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: variations on a theme Oncogene 27 2008 5497 5510
21. G. Singer, R.J. Kurman, H.W. Chang, S.K. Cho, and M. Shih Ie Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 160 2002 1223 1228
22. G. Singer, R. Oldt III, and Y. Cohen Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
23. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
24. K. Nakayama, N. Nakayama, and R.J. Kurman Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms Cancer Biol Ther 5 2006 779 785
25. K. Nakayama, Y. Takebayashi, and K. Hata The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma Anticancer Res 23 2003 4657 4662
26. K. Nakayama, K. Miyazaki, A. Kanzaki, M. Fukumoto, and Y. Takebayashi Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines Oncol Rep 8 2001 1285 1287
27. N. Mori, S. Kyo, and J. Sakaguchi Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosis Cancer Sci 98 2007 1881 1888
28. D.L. Dai, M. Martinka, and G. Li Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases J Clin Oncol 23 2005 1473 1482
29. O. David, J. Jett, and H. LeBeau Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage Clin Cancer Res 10 2004 6865 6871
30. S.Y. Li, M. Rong, F. Grieu, and B. Iacopetta PIK3CA mutations in breast cancer are associated with poor outcome Breast Cancer Res Treat 96 2006 91 95
31. N. Maruyama, Y. Miyoshi, and T. Taguchi Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women Clin Cancer Res 13 2007 408 414
32. F. Di Nicolantonio, S. Arena, and J. Tabernero Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus J Clin Invest 120 2010 2858 2866
33. D. Maeda, T.L. Mao, and M. Fukayama Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma Int J Mol Sci 11 2010 5120 5128
34. B. Guan, T.L. Wang, and IeM. Shih ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers Cancer Res 71 2011 6718 6727
35. A. Katagiri, K. Nakayama, and M.T. Rahman Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma Mod Pathol 25 2012 282 288